PharmAust Limited EBIT

PharmAust Limited (PAA.AX) currently reports a EBIT of $-45M as of June 2026. That compares with $-16M in the prior-year period — down 175.2% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore PharmAust Limited's EBIT history and peer comparisons.

PharmAust Limited's EBIT decreased from $-16M to $-45M — a 175.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PharmAust Limited's EBIT of $-45M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PharmAust Limited reported $-45M in EBIT as of June 2026. That compares with $-16M in the prior-year period — down 175.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-45M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for PharmAust Limited, and consider following PAA.AX for alerts when major investors trade the stock.